Gurpreet Singh

Gurpreet Singh

Auto-generated profile, based on publicly available information

Gurpreet Singh

Department of Psychiatry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur, Malaysia

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2014 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
PDF file
RKRamandeep Kaur
Ramandeep Kaur
PKPrabhkirat Kaur
Prabhkirat Kaur
Sahil SharmaSahil Sharma
Sahil Sharma
GSGurpreet Singh
Gurpreet Singh
SMSamir Mehndiratta
Samir Mehndiratta
KNKunal Nepali
Kunal Nepali
Pyrimidine ring is the building unit of DNA and RNA and thus pyrimidine based chemical architectures exhibit diverse pharmacological activities. Among the reported medicinal attributes of pyrimidines, anticancer activity is the most extensively reported. The anticancer potential of pyrimidines in fused scaffolds has also been evidenced through number of research article and patent literature. The pyrimidines based scaffolds have exerted their cell killing effects through varied mechanisms which indicate their potential to interact with diverse enzymes/ targets/receptors. This review article strictly focuses on the patent literature from 2009 onwards. The structure of the potent compounds, their IC50 values, models/assays used for the anticancer evaluation and the enzymes/ receptors/ targets involved have been presented in this compilation. Significant number of patents i.e. 59 have been published on pyrimidine based anticancer agents from 2009-2014 (from 2009 through the present date) which clearly indicate that this heterocycle is an area of focus at present for researchers all over the globe. Moreover, out of the 59 patents published during this period, 32 have been published from 2012 onwards which further highlights the present interest of the researcher towards pyrimidine based anticancer agents. The promising activity displayed by these pyrimidine based scaffolds clearly places them in forefront as potential future drug candidates. The present compilation can be extremely beneficial for the medicinal chemists working on design and synthesis of anticancer drugs.

1 October 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
VSVISHAL SHARMA
VISHAL SHARMA
GSGurpreet Singh
Gurpreet Singh
HKHarpreet Kaur
Harpreet Kaur
ASAjit K. Saxena
Ajit K. Saxena
MIMohan Paul S. Ishar
Mohan Paul S. Ishar

11 February 2016 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
SMSamir Mehndiratta
Samir Mehndiratta
SSSameer Sapra
Sameer Sapra
GSGurpreet Singh
Gurpreet Singh
MSManwinder Singh
Manwinder Singh
KNKunal Nepali
Kunal Nepali
Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), Hedgehog-Gli Signaling, polo like kinase (PLKs) and protein kinase B (PKB)/Akt. Compounds based on quinazolines have shown efficacies in µM to nM range in various cancer cell lines and could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorised based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.

1 January 2015 in Advanced Biomedical Research
Verified
Journal Article
Open access
GSGurpreet Singh
Gurpreet Singh
RDRadheyS Dhuria
RadheyS Dhuria
AKAnudeep Kaur
Anudeep Kaur
RKRamandeep Kaur
Ramandeep Kaur
TKTanurajvir Kaur
Tanurajvir Kaur
Ast few years. For better understanding, appropriate animal models that closely mimic the changes in humans needed, as vital tool for understanding the etiology and pathogenesis of the disease at the cellular/molecular level and for preclinical testing of drugs. This review aims to describe the animal models of type-1 diabetes (T1Ds) and T2Ds to mimic the causes and progression of the disease in humans. And also we highlight patent applications published in the last few years related to animal models in diabetes as an important milestone for future therapies that are aim to treating diabetes with specific symptoms and complications....

1 June 2018 in Heliyon
Verified
Journal Article
Open access
DKDinesh Kumar
Dinesh Kumar
PSpooja Sharma
pooja Sharma
KNKunal Nepali
Kunal Nepali
GMGirish Mahajan
Girish Mahajan
MMMubashir J. Mintoo
Mubashir J. Mintoo
Fidele Ntie-KangFidele Ntie-Kang
Fidele Ntie-Kang
In an effort to discover an effective and selective antitumour agent, synthesis and anti-cancer potential of 4-(pyridin-4-yl)-6-(thiophen-2-yl) pyrimidin-2(1H)-one (SK-25), which has been reported earlier by us with significant cytotoxicity towards MiaPaCa-2 malignant cells, with an IC50 value of 1.95 μM and was found to instigate apoptosis. In the present study, the antitumour efficacy of SK-25 was investigated on Ehrlich ascites tumour (EAT, solid), Sarcoma 180 (solid) tumour and Ehrlich ascites carcinoma. The compound was found to inhibit tumour development by 94.71% in Ehrlich ascites carcinoma (EAC), 59.06% in Ehrlich tumour (ET, solid) and 45.68% in Sarcoma-180 (solid) at 30 mg/kg dose. Additionally, SK-25 was established to be non-toxic at a maximum tolerated dose of 1000 mg/kg in acute oral toxicity in Swiss-albino mice. Computer-based predictions also show that the compounds could have an interesting DMPK profile since all 51 computed physicochemical parameters fall within the recommended range for 95% of known drugs. The current study provides insight for further investigation of the antitumour potential of the molecule.

16 November 2016 in Journal of Chemical Biology
Verified
Journal Article
Closed access
PDF file
SSShweta Sharma
Shweta Sharma
VSVishal Sharma
Vishal Sharma
GSGurpreet Singh
Gurpreet Singh
HKHarpreet Kaur
Harpreet Kaur
SSShubham Srivastava
Shubham Srivastava
MIMohan Paul S. Ishar
Mohan Paul S. Ishar